Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 283

Sort by

Sort Order Select

Journal Articles

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 5980.

https://doi.org/10.1182/blood-2025-5980

Published: 2025

Journal Articles

Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party

Evgenii Shumilov, Maud Ngoya, Philipp Berning, Irma Khvedelidze, Sridhar Chaganti, Regis Peffault De Latour, Kate Cwynarski, Laura Magnano, Frank Kroschinsky, Johannes Clausen, José Antonio Pérez-Simón, Lawrence Ng, Luca Castagna, Georg Lenz, Anna Sureda, Gandhi Damaj, Ali Bazarbachi, Norbert Schmitz

Blood (2025) 146 (Supplement 1): 891.

https://doi.org/10.1182/blood-2025-891

Published: 2025

Journal Articles

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 881.

https://doi.org/10.1182/blood-2025-881

Published: 2025

Journal Articles

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Blood (2025) 146 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2025-1427

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2025-1842

Published: 2025

Journal Articles

Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.

Blood (2025) 146 (Supplement 1): 112.

https://doi.org/10.1182/blood-2025-112

Published: 2025

Journal Articles

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Blood (2025) 146 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2025-2526

Published: 2025

Journal Articles

Consistent benefits of pegcetacoplan treatment in PNH patients with and without a history of aplastic anemia in real world: Analysis of the ongoing COMPLETE Phase IV observational study

Roochi Trikha, Lenka Mastikova, Carmen Gonzalez-Gonzalez, Anna-Elina Lehtinen, Elena Surova, Shamil Sadikhov, Michael O'Malley, Regis Peffault De Latour

Blood (2025) 146 (Supplement 1): 1113.

https://doi.org/10.1182/blood-2025-1113

Published: 2025

Journal Articles

Serum ferritin changes in iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria

Antonio Risitano, Carlos de Castro, Camilla Frieri, Bing Han, Richard Kelly, Austin Kulasekararaj, Jaroslaw Maciejewski, Vinod Pullarkat, Alexander Röth, Phillip Scheinberg, Flore Sicre-de-Fontbrune, Yasutaka Ueda, Tim Costigan, Marion Dahlke, Philippe Ferber, Tomasz Lawniczek, Stefanie Senger, Regis Peffault De Latour

Blood (2025) 146 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2025-4974

Published: 2025

Journal Articles

The global PNH patient registry: real-world data on PNH symptom burden and quality of life

David Araten, Austin Kulasekararaj, Jun-ichi Nishimura, Regis Peffault De Latour, Jeff Szer, Ilene Weitz, Azalea Candelaria, Aliza Fink, Alice Houk, Elizabeth Kottke, Brad Wong

Blood (2025) 146 (Supplement 1): 2697.

https://doi.org/10.1182/blood-2025-2697

Published: 2025

Journal Articles

The CSMD1 gene is involved in hematopoietic stem cell HSC pruning in patients with acquired immune-mediated aplastic anemia

Antonio Risitano, Deniz Ece Kaya, Simona Iacobelli, Riley Cook, Giorgio Napolitani, Sila Gerlevik, Mohammad M Karimi, Nogayhan Seymen, Flore Sicre-de-Fontbrune, Morag Griffin, Camilla Frieri, Carlo Dufour, Regis Peffault De Latour, Ghulam Mufti, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 4982.

https://doi.org/10.1182/blood-2025-4982

Published: 2025

Journal Articles

Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial

Blood (2025) 146 (Supplement 1): 4981.

https://doi.org/10.1182/blood-2025-4981

Published: 2025

Journal Articles

Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy

Regis Peffault De Latour, Carlos de Castro, Richard Kelly, Austin Kulasekararaj, Alexander Röth, Phillip Scheinberg, Yasutaka Ueda, Douglas Applegate, Marion Dahlke, Philippe Ferber, Imelda Schuhmann, Antonio Risitano

Blood (2025) 146 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2025-4979

Published: 2025

Journal Articles

The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program

Regis Peffault De Latour, Carlos de Castro, Anna Gaya, Morag Griffin, Bing Han, Austin Kulasekararaj, Jaroslaw Maciejewski, Bhumika Patel, Alexander Röth, Phillip Scheinberg, Hubert Schrezenmeier, Yasutaka Ueda, Tim Costigan, Marion Dahlke, Philippe Ferber, Rajeshri Karki, Luca Monaco, Silvia Sanz, Antonio Risitano

Blood (2025) 146 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2025-4978

Published: 2025

Journal Articles

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2025-4288

Published: 2025

Journal Articles

Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)

Blood (2025) 146 (Supplement 1): 6066.

https://doi.org/10.1182/blood-2025-6066

Published: 2025

Journal Articles

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Blood (2025) 146 (Supplement 1): 6041.

https://doi.org/10.1182/blood-2025-6041

Published: 2025

Journal Articles

Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from Phase 2 studies who entered the roll-over extension program

Antonio Risitano, Camilla Frieri, Bor-Sheng Ko, Lily Wong Lee Lee, Alexander Röth, Flore Sicre-de-Fontbrune, Eng Soo Yap, Sung-Soo Yoon, Philippe Ferber, Irina Baltcheva, Aurelie Verles, Silvia Sanz, Luca Monaco, Tim Costigan, Regis Peffault De Latour

Blood (2025) 146 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2025-3198

Published: 2025

Journal Articles

Frequency and impact of FLT3-ITD microclones in younger AML patients

Blood (2025) 146 (Supplement 1): 456.

https://doi.org/10.1182/blood-2025-456

Published: 2025

Journal Articles

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Blood (2025) 146 (Supplement 1): 5294.

https://doi.org/10.1182/blood-2025-5294

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Consistent benefits of pegcetacoplan treatment in PNH patients with and without a history of aplastic anemia in real world: Analysis of the ongoing COMPLETE Phase IV observational study

Serum ferritin changes in iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria

The global PNH patient registry: real-world data on PNH symptom burden and quality of life

The CSMD1 gene is involved in hematopoietic stem cell HSC pruning in patients with acquired immune-mediated aplastic anemia

Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial

Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy

The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from Phase 2 studies who entered the roll-over extension program

Frequency and impact of FLT3-ITD microclones in younger AML patients

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only